Full-Time
Associate Director/Director
Technology Transfer
Posted on 9/24/2025
Asimov
51-200 employees
Genetic design software with engineered cells
No salary listed
Boston, MA, USA
Hybrid
Hybrid position requiring some in-office presence.
 Biology & Biotech (4) |
|---|
| , , , |
- Advanced degree (MSc or PhD) in a relevant scientific or engineering discipline (e.g., Biochemical Engineering, Chemical Engineering, Biotechnology, Biochemistry, Biology)
- Minimum of 10 years of experience in the biopharmaceutical or life sciences industry, with at least 5 years specifically in cell line development
- Direct experience in a CDMO environment is highly preferred, including customer-facing interactions or proven experience transferring technology between independent sites
- Strong leadership, communication, interpersonal, and presentation skills
- Excellent project management abilities, with a proven capacity to manage timelines, budgets, and resources effectively
- Knowledge of cGMP, FDA, EMA, and ICH guidelines
- Strong analytical, problem-solving, and decision-making skills
- Ability to work effectively in a fast-paced, dynamic, and collaborative environment
- Demonstrated ability to build and maintain strong working relationships with clients and internal stakeholders
- Strategic thinker with a proactive and results-oriented approach
- Provide expert technical guidance on tech-out evaluation design, CLD planning, scale-up, optimization, and troubleshooting for various biopharmaceutical manufacturing processes (e.g., mammalian cell culture, purification, analytical methods, and viral vector production)
- Work cross-functionally with internal departments (CLD, DNASC, Process Development, Analytical Development, Quality, Facilities, Business Development) to ensure project success
- Oversee the preparation and review of critical documentation, including tech transfer plans, protocols, CLD reports, cell history documentation, and drug master filings
- Develop and implement standardized tech transfer procedures, protocols, and best practices
- Work with functional leads and teams to drive the implementation of new technologies and innovative approaches to enhance tech transfer efficiency and capability
- Support customer inspections, audits, and related site visits at our site in Boston
- Represent the company at industry conferences, networking events, and in discussions with potential partners
- Stay abreast of industry developments, emerging technologies, and competitive dynamics to inform company strategy
- Collaborate closely with Business Development to assess new project opportunities and provide technical expertise
- This role is expected to involve up to 20% travel, primarily to customer sites and conferences
- Additional experience in areas such as technology transfer, process development, or manufacturing sciences within a CDMO or pharmaceutical/biotech company is a plus
- Direct experience in a CDMO environment is highly preferred, including customer-facing interactions or proven experience transferring technology between independent sites
What Asimov does: It provides an integrated synthetic biology platform for biopharma, combining cloud-based software for designing, simulating, and optimizing genetic systems with engineered GMP host cells used for therapeutic production. How its products work: The software lets users design and run simulations of genetic circuits and optimize production processes, while engineered cell lines are used to express proteins or produce viral vectors; services include process development and stability studies. How it differs from competitors: It bundles an end-to-end suite—genetic design software, in-house cell-line development, and process development—along with a performance guarantee, such as a 4 g/L monoclonal antibody titer promise, reducing client risk. What its goal is: To help biopharma customers achieve high yields and scalable production of biologics, gene therapies, and programmable medicines through a tightly integrated platform.
Company Size
51-200
Company Stage
Series B
Total Funding
$204.7M
Headquarters
Boston, Massachusetts
Founded
2017
Simplify's Take
What believers are saying
- Licensed LV Edge to AGC Biologics in January 2026 for scalable viral production.
- CHO Edge delivers 8-12 g/L titers; AAV Edge hits 6E15 vg/L for therapies.
- Partners with 25+ biopharma firms, expanding via Boulder office for 95 employees.
What critics are saying
- Ginkgo Bioworks undercuts with cheaper biofoundries, eroding titers in 12-24 months.
- Twist Bioscience commoditizes software at $0.09/bp, capturing market in 6-12 months.
- FDA 2025 purity mandate triggers LV Edge recalls due to integration variability in 6-12 months.
What makes Asimov unique
- Asimov integrates mammalian synthetic biology, CAD software, and ML for genetic design.
- LV Edge achieves E9 TU/mL lentiviral titers with stable cell lines, no transfection.
- Acquired MIT Foundry in 2023 to pioneer advanced genetic circuits at Asimov Labs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -5%BOSTON--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service. There are now two ways for customers to access Asimov’s cell line technology to minimize cost and manufacturing risk, depending on their needs:The LV Edge Packaging System, launched earlier this year, which enables a single plasmid transfection that achieves E8 TU/mL.The new, fully-stable LV Edge Producer cell line development service, which generates clones that achieve E9 TU/mL with no transient transfection required.The LV Edge Producer System completely eliminates GMP plasmid cost and greatly reduces process complexity and variability by stably integrating all the genes for lentiviral production into the host cell. Current processes for lentiviral production are inherently scale-limited and variable due to the need for multi-plasmid transient transfection. Furthermore, the reliance on GMP plasmids and transfection reagents substantially increases costs and introduces supply chain and product variability risks. The development of a fully stable cell line technology enables scalable, reproducible and low-cost production of lentivirus, which will unlock applications for larger therapeutic indications
The Foundry, formerly of MIT and the Broad Institute, has joined Asimov; its team, leadership, and infrastructure have moved to Asimov's Boston headquarters.headquarters. The group has nucleated Asimov Labs, a new R&D center for advanced genetic design.BOSTON, Aug. 2, 2023 /PRNewswire/ -- Asimov, the synthetic biology company building tools to design living systems, announced today that The Foundry, previously of MIT and the Broad Institute, has joined its ranks. The Foundry was established by Professor Christopher Voigt (MIT) in 2012 as part of DARPA's Living Foundries program to expand the limits of genetic design. During its tenure, the Foundry developed novel engineering techniques and used them to produce thousands of molecules, materials, genetic circuits, and sensors. In its new home at Asimov, the team will continue to pioneer genetic design as Asimov Labs, a center dedicated to developing technologies to open new frontiers for biological engineering.The Foundry, formerly of MIT and the Broad Institute, has joined AsimovAsimov develops cellular, genetic, and computational tools to enable next-generation therapeutics
LatchBio founders: Alfredo Andere, Kenny Workman, and Kyle Giffin. LatchBioMost industries today are experiencing an unprecedented data deluge – and synthetic biology is no exception. Twenty years ago, a typical biological experiment generated 3-5 megabytes of information. Today, a routine synthetic biology workflow produces anywhere from 1,000 to 40,000 terabytes. That is a billion times more data! Such a large number of data points is simply impossible to interpret by human eye. This is why almost every bio lab today has to set up custom bioinformatics pipelines, invest in cloud computing, and master advanced data visualization software – all that just to see the results of their experiments.A San Francisco startup, LatchBio, hopes to make data analysis much easier for biologists with its full-stack biocomputing infrastructure
Image/Anastasiia SlynkoThe companies Apogee Therapeutics, Pulmocide and Qitan Technology bagged the biggest biotech investments in December 2022. Around the world, immunology and manufacturing players attracted the biggest funding rounds.We’ve hit 2023 and a lot of biotech fundraising took place in the final month of 2022. We’ve gathered the biggest biotech investments that went to private companies around the world and split them into healthcare and industrial biotechnology-focused verticals.Healthcare investmentsThe U.S.’ top private biotech healthcare investment went to Apogee Therapeutics. The Paragon Therapeutics spinout took home $149 million in a Series B round to fund the development of drugs for a range of undisclosed immunological and inflammatory conditions.An honorable mention goes to Alpha9 Theranostics based in the U.S.’s neighbor, Canada. The firm raised $75 million in a bid to develop radiopharmaceutical treatments for cancer.The top European biotech healthcare investment round went to Pulmocide in the U.K. The firm’s $52 million Series C round will be used to finance the development of inhaled drugs treating viral and fungal infections in the respiratory tract.Content continues below Related ContentThe Chinese firm MaxVax topped the healthcare biotech investment list in Asia-Pacific with a $43 million investment in December 2022
“Before COVID, if I said we need to reproduce or scale, people would ask, why?” says Doug Densmore, Co-Founder of Lattice Automation and Asimov. “Now, people get it.” The consequence? An automated revolution in biotechnology, where cheap computing meets mass-reproducible synthetic biology, begetting an industry with the potential to surpass anything that went before it. The opportunity is […]